Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert

Long-term outcomes and complications of posterior chamber phakic intraocular lens implantation for the correction of high myopia and astigmatism (5 year study)

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Phakic IOLs III

Session Date/Time: Tuesday 13/09/2016 | 09:30-11:00

Paper Time: 10:50

Venue: Poster Village: Pod 4

First Author: : S.Hashemian IRAN

Co Author(s): :                  

Abstract Details


To evaluate refractive and visual outcomes and complications associated with Implantable Collamer Lens (ICL) and toric ICL implantation to correct high myopia and astigmatism.


Eye research center Rassoul Akram hospital, Iran University of medical sciences and Iranian Eye Clinic, Tehran, IRAN.


Uncorrected distance visual acuity (UDVA) and corrected distance visual acuity (CDVA), refraction, and adverse effects were evaluated in 66 eyes of 31 high myopic patients after 5 years with Visian ICMV4 pIOL (STAAR Surgical Inc.)


The mean preoperative SE and cylinder changed from -11.74  5.36 D and -2.35 1.58 D to –1.53  1.48 D and -0.82  0.69 D, respectively 5 years postoperatively. Before the surgery the mean decimal CDVA was .58  0.31. The mean UDVA and CDVA changed to 0.61  0.32 and 0.76  0.31, respectively. 56.7% of eyes achieved 20/40 or better UDVA postoperatively. The mean safety and efficacy indices were 1.29 and 1.04 respectively. No eye lost a line of visual acuity and 42 eyes gained one or more lines. 11% Endothelial cell loose was occurred. Transient high intraocular pressure was observed in 3 patients, and 4 eyes had needed realignment. Crystalline lens was clear during the study.


ICL and toric ICL implantations were effective, predictable, and safe procedures over the long term follow up for the treatment of high myopia and high myopic astigmatism.

Financial Disclosure:


Back to previous